Low dose rate neutron radiotherapy using fast neutrons emitted by the radionuclide 252Cf was combined with fractionated X- or gamma rays for the radiotherapy of advanced cervicovaginal tumors. Two different implant schedules were tested to determine the response of the tumors to the scheduling of therapy with the 252Cf either early or delayed in the fractionatedradiotherapy course. A 90% frequency of complete local clearance of pelvic tumors was observed by the early application of 252Cf. Neutron curietherapy applied as a boost treatment at the end of fractionated radiotherapy, resulted in only 40% local control. Improved results were observed by early implantation therapy and is postulated to be the result of more effective hypoxic tumor therapy and reoxygenation of the hypoxic pelvic tumor. The two groups of patients were compared as to their general status and medical condition and were found similar in age, frequency of associated disease, body weight and tumor stage. The failures of local control by early 252Cf neutron therapy, occured in 2 patients with high-stage tumor and severe vascular disease and suggests that tumor response was partly dependent upon the integrity and elasticity of the small vessel system.

This content is only available via PDF.
© 1982 S. Karger AG, Basel
1982
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.